| Trial | control | p<0.05 | harm | NS |
|---|
| Garber, 2006 | vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| vs rosiglitazone (add on MET) | | | |
| Trial | Treatments | Patients | Method |
|---|
| Garber, 2006 | metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg) (n=-9) vs. metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg, depending on previous treatment) (n=-9) | patients with type 2 diabetes inadequately controlled on metformin monotherapy | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 24 weeks |
| Garber, 2002 | glyburide 2.5 mg (n=-9) vs. placebo (n=-9) | patients with type 2 diabetes who had failed diet and exercise | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| Vray, 1995 | glibenclamide (2.5 mg X 3/d) (n=-9) vs. placebo (n=-9) | type 2 diabetic outpatients, 40-70 years of age, treated by diet alone or oral anti-diabetic drugs | double-blind Factorial plan Sample size: -9/-9 Primary endpoint: FU duration: |
| Hermann, 1991 | metformin + glibenclamide (n=-9) vs. metformin (n=-9) metformin, glibenclamide or the combination of both | patients with non-insulin-dependent diabetes mellitus | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 6 months |
| DeFronzo, 1995 | metformin and glyburide (n=-9) vs. metformin (n=-9) metformin and glyburide vs. metformin vs. glyburide | patients with non-insulin-dependent diabetes mellitus | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 29 weeks |
| Erle, 1999 | low-dose glyburide plus metformin (n=-9) vs. high-dose glyburide alone (n=-9) | | Cross over Sample size: -9/-9 Primary endpoint: FU duration: |
| Marre (ass), 2002 | metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg, titrated with the intention to achieve fasting plasma glucose (FPG) < or = 7 mmol/l (n=-9) vs. metformin 500 mg, (n=-9) metformin 500 mg, glibenclamide 5 mg, metformin-glibenclamide 500 mg/2.5 mg or metformin-glibenclamide 500 mg/5 mg | patients with Type 2 diabetes mellitus inadequately controlled by metformin monotherapy | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 16 weeks |
| Blonde, 2002 | glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg (n = 162) (n=-9) vs. metformin 500 mg (n=-9) glyburide 10 mg b.i.d. (n = 164); metformin 500 mg (n = 153); glyburide/metformin 2.5 mg/500 mg (n = 160); or glyburide/metformin 5 mg/500 mg | patients with inadequate glycaemic control on at least half-maximal dose of sulphonylurea | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 16 weeks |
| Tosi, 2003 | metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d (n=-9) vs. metformin (500 to 3,000 mg/d), (n=-9) metformin (500 to 3,000 mg/d), glibenclamide (5 to 15 mg/d), or their combination (metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d | | double-blind Cross over Sample size: -9/-9 Primary endpoint: FU duration: 6 months |
| Garber, 2003 | glyburide/metformin (n=-9) vs. metformin (n=-9) glyburide/metformin tablets vs. metformin or glyburide monotherapy | patients with type 2 diabetes who had inadequate glycemic control [glycosylated hemoglobin A(1C) (A1C), >7% and <12%) with diet and exercise alone | Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
